116 research outputs found
A High-resolution depth model for the North West Shelf and Outer Browse Basin (20210025C)
No full textMaintenance and Update Frequency: asNeededStatement: This dataset was produced using Python 2.7 and ArcGIS 10.5
The vertical datum is MSL while the horizontal datum is WGS84 UTM-50S.
For additional metadata questions, please download the Metadata.txt file and the lineage shapefile located with the dataset.
Processing methodology:
The detailed methodology is presented in the journal article located with the dataset<b>Purpose</b><br/>Client RequestThis resource contains a bathymetry compilation prepared by the University of Western Australia for the North West Shelf of Australia, between the Cape Range and the Dampier Peninsula. <br/><br/>The compilation includes, by decreasing resolution:<br/>- Publicly available MBES datasets, made available by Geoscience Australia by December 2019.<br/>- Satellite derived bathymetry produced using 1000+ images acquired between January 2017 and December 2019.<br/>- Seismic derived bathymetry extracted from 100+ surveys acquired between 1981 and 2015.<br/>- SRTM topography, reprocessed by Galant et al, 2011: https://pid.geoscience.gov.au/dataset/ga/72759<br/>- 2009 Australian Bathymetry and Topography grid: https://pid.geoscience.gov.au/dataset/ga/67703<br/><br/>The Seismic and Satellite derived bathymetry grids are also available as individual layers.<br/><br/>The vertical and spatial accuracy of the datasets have been thoroughly assessed using high-resolution datasets including publicly available MBES and LADS surveys. The assessment indicates that the seismic derived bathymetry has a depth accuracy better than 1 m + 2% of the absolute water depths while the satellites derived bathymetry has a depth accuracy better than 1 m + 5% of the absolute water depths. <br/><br/>A detailed methodology is provided in: Lebrec et al, 2021. Towards a regional high-resolution bathymetry of the North West Shelf of Australia based on Sentinel-2 satellite images, 3D seismic surveys and historical datasets. (https://doi.org/10.5194/essd-13-5191-2021)<br/><br/>This dataset is published with the permission of the CEO, Geoscience Australia.<br/><br/>AUTHOR’S NOTICE: <br/>This dataset should not be used, under any circumstances, for navigation.<br/>When used, the dataset should be referenced as follow:<br/>Lebrec, U., Paumard, V., O'Leary, M. J., and Lang, S. C.: Towards a regional high-resolution bathymetry of the North West Shelf of Australia based on Sentinel-2 satellite images, 3D seismic surveys and historical datasets, Earth Syst. Sci. Data Discuss. [preprint], https://doi.org/10.5194/essd-2021-128, in review, 2021
Inclusion of a priori information in genome‐wide association analysis
No full textGenome-wide association studies (GWAS) continue to gain in popularity To utilize the wealth of data created more effectively, a variety of methods have recently been proposed to include a priori information (e.g., biologically interpretable sets of genes, candidate gene information, or gene expression) in GWAS analysis. Six contributions to Genetic Analysis Workshop 16 Group 11 applied novel or recently proposed methods to GWAS of rheumatoid arthritis and heart disease related phenotypes. The results of these analyses were a variety of novel candidate genes and sets of genes, in addition to the validation of well-known genotype-phenotype associations. However, because many methods are relatively new, they would benefit from further methodological research to ensure that they maintain type I error rates while increasing power to find additional associations. When methods have been adapted from other study types (e.g., gene expression data analysis or linkage analysis), the lessons learned there should be used to guide implementation of techniques. Lastly, many open research questions exist concerning the logistic details of the origin of the a priori information and the way to incorporate it. Overall, our group has demonstrated a strong potential for identifying novel genotype-phenotype relationships by including a priori data in the analysis of GWAS, while also uncovering a series of questions requiring further research
Diagnostic performance of Baveno IV criteria in cirrhotic patients with upper gastrointestinal bleeding : analysis of the F7 liver-1288 study population
No full textBACKGROUND & AIMS:
The definition of failure to control bleeding agreed upon at the Baveno IV consensus meeting, included the Adjusted Blood Requirement Index [ABRI: number of blood units/(final-initial hematocrit+0.01)]. ABRI ≥0.75 denotes failure. However, timing for hematocrit measurements was not defined. The aims of this study were: (1) to assess the Baveno IV criteria performance to classify treatment success or failure to control bleeding at 5 days, (2) to determine the appropriate timing for hematocrit.
METHODS:
Two hundred and forty-two cirrhotic patients with gastrointestinal bleeding were independently classified by three clinical experts according to the Baveno IV criteria, by analysis of the database of a randomized trial. ABRI was calculated by using the closest hematocrit to the 5 day time point from the first trial product administration (ABRI-1) or after the latest transfusion within the 5-day period (ABRI-2). The gold standard for success/failure for 5-day control of bleeding was the clinical judgment of the three independent observers based on all the clinical and follow-up data.
RESULTS:
Inter-observer agreement for the final outcome assessment was 0.82 and a final consensus was obtained in 236/242 patients. Inter-observer agreement on patient classification with Baveno IV criteria was 0.70 with ABRI-1 and 0.84 with ABRI-2. c-statistics for correct patients classification were 0.86 for ABRI-1, 0.84 for ABRI-2, and 0.88 for Baveno IV criteria without ABRI. ABRI-1 caused misclassification of 27 patients and ABRI-2 of 39.
CONCLUSIONS:
Baveno IV criteria are accurate to assess outcome of patients with variceal bleeding. There is a substantial observer variability linked to timing of hematocrits for ABRI calculation. With the current definition ABRI does not add to the performance of the other criteria
Diagnostic performance of Baveno II/III and Baveno IV criteria in cirrhotic patients with gastrointestinal bleeding. Analysis of the F7 liver-1288 study population
No full textTowards a regional high-resolution bathymetry of the North West Shelf of Australia based on Sentinel-2 satellite images, 3D seismic surveys, and historical datasets
No full textHigh-resolution bathymetry forms critical datasets for marine geoscientists.
It can be used to characterize the seafloor and its marine habitats, to
understand past sedimentary records, and even to support the development of
offshore engineering projects. Most methods to acquire bathymetry data are
costly and can only be practically deployed in relatively small areas. It is
therefore critical to develop cost-effective and advanced techniques to
produce regional-scale bathymetry datasets.
This paper presents an integrated workflow that builds on satellites images
and 3D seismic surveys, integrated with historical depth soundings, to
generate regional high-resolution digital elevation models (DEMs). The
method was applied to the southern half of Australia's North West Shelf and
led to the creation of new high-resolution bathymetry grids, with a
resolution of 10 × 10 m in nearshore areas and 30 × 30 m elsewhere.
The vertical and spatial accuracy of the datasets have been assessed using
open-source Laser Airborne Depth Sounder (LADS) and multibeam echosounder
(MBES) surveys as a reference. The comparison of the datasets indicates that
the seismic-derived bathymetry has a vertical accuracy better than 1 m + 2 % of the absolute water depth, while the satellite-derived bathymetry
has a depth accuracy better than 1 m + 5 % of the absolute water depth.
This 30 × 30 m dataset constitutes a significant improvement of the
pre-existing regional 250 × 250 m grid and will support the onset of
research projects on coastal morphologies, marine habitats, archaeology, and
sedimentology.
All source datasets are publicly available, and the methods are fully
integrated into Python scripts, making them readily applicable elsewhere in
Australia and around the world. The regional digital elevation model and the
underlying datasets can be accessed at https://doi.org/10.26186/144600 (Lebrec et al., 2021).</p
Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes
No full textBackground/Aims: We assessed whether cognitive and functional decline in community-dwelling patients with mild Alzheimer disease (AD) dementia were associated with increased societal costs and caregiver burden and time outcomes. Methods: Cognitive decline was defined as a ≥3-point reduction in the Mini-Mental State Examination and functional decline as a decrease in the ability to perform one or more basic items of the Alzheimer’s Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) or ≥20% of instrumental ADL items. Total societal costs were estimated from resource use and caregiver hours using 2010 costs. Caregiver burden was assessed using the Zarit Burden Interview (ZBI); caregiver supervision and total hours were collected. Results: Of 566 patients with mild AD enrolled in the GERAS study, 494 were suitable for the current analysis. Mean monthly total societal costs were greater for patients showing functional (+61%) or cognitive decline (+27%) compared with those without decline. In relation to a typical mean monthly cost of approximately EUR 1,400 at baseline, this translated into increases over 18 months to EUR 2,254 and 1,778 for patients with functional and cognitive decline, respectively. The number of patients requiring supervision doubled among patients showing functional or cognitive decline compared with those not showing decline, while caregiver total time increased by 70 and 33%, respectively and ZBI total score by 5.3 and 3.4 points, respectively. Conclusion: Cognitive and, more notably, functional decline were associated with increases in costs and caregiver outcomes in patients with mild AD dementia
Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension
No full textPosition pape
Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials
No full textAIMS:
Patients with a type-2-diabetes (T2D) phenotype positive for glutamic acid decarboxylase antibodies (GADA) represent the majority of cases of latent autoimmune diabetes of the adult (LADA). The GLP-1 receptor agonist dulaglutide, recently introduced for treatment of T2D, has yet to be evaluated in LADA patients. Our primary objective was to evaluate the effect of dulaglutide on glycaemic control (HbA1c) in GADA-positive LADA vs GADA-negative T2D patients.
METHODS:
A post-hoc analysis was performed using data from 3 randomized phase 3 trials (AWARD-2,-4,-5; patients with GADA assessment) which were part of the dulaglutide clinical development programme in T2D. LADA patients were identified by GADA ≥5 IU/mL (ELISA). Changes in HbA1c during 12 months of treatment with dulaglutide or comparator were analysed using mixed-effect model repeated measures.
RESULTS:
Of 2466 adults tested for GADA (dulaglutide, 1710; glargine, 298; sitagliptin, 294; placebo, 164), 2278 (92.4%) were GADA-negative and 188 (7.6%) were GADA-positive, including 58 GADA-high patients (> 200 IU/mL) and 130 GADA-low patients (≤200 and ≥5 IU/mL). Overall, baseline parameters were comparable between the groups. Dulaglutide resulted in comparable HbA1c reductions in GADA-negative (LS mean change [95%CI], -1.09% [-1.15, -1.03]) and GADA-positive patients (-0.94% [-1.15, -0.72]) at 12 months. HbA1c reductions were numerically, but not statistically, significantly larger in GADA-low patients (-1.02% [-1.26, -0.78]) vs GADA-high patients (-0.72% [-1.21,-0.24]) at 12 months. Similar outcomes were observed at 3 and 6 months.
CONCLUSIONS:
These data are the first to indicate that dulaglutide was effective in reducing HbA1c in LADA patients
- …
